Levosimendan in acute decompensation of anthracycline-induced cardiotoxicity

International Journal of Cardiology

Volumn 118, Issue 3, 2007, Pages 406-407

  Garcia, José A P ^a   Simvoulidis, Luiz F N ^a   Salluh, Jorge I F ^a,b   Hansen, Maria H A ^a   Feres, Guilherme A ^a   Holanda, Gustavo S ^a   Souza, Roberto C S ^a   Toscano, Luisa ^a   Soares, Márcio ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b Hospital Barra D'Or   (Brazil)

Author keywords

Anthracycline induced cardiotoxicity; Cancer; Doxorubicin; Heart failure; Levosimendan

Indexed keywords

ANTHRACYCLINE; DESLANOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOXORUBICIN; FUROSEMIDE; LEVOSIMENDAN; SPIRONOLACTONE;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CASE REPORT; FEMALE; HEART FAILURE; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; LUNG EDEMA; MYOCARDIAL DISEASE; PLEURA EFFUSION; PRIORITY JOURNAL; TACHYCARDIA; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

ACUTE DISEASE; ADULT; ANTHRACYCLINES; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; PYRIDAZINES; TREATMENT OUTCOME;

EID: 34247602636     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.07.051     Document Type: Article

References (10)

1. Singal P.K., and Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 339 (1998) 900-905
2. Follath F., Cleland J.G., Just H., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO-study): a randomised double-blind trial. Lancet 360 (2002) 196-202
3. Lehmann A., Boldt J., and Kirchner J. The role of Ca++-sensitizers for the treatment of heart failure. Curr Opin Crit Care 9 (2003) 337-344
4. Noto A., Giacomini M., Palandi A., Stabile L., Reali-Forster C., and Iapichino G. Levosimendan in septic cardiac failure. Intensive Care Med 31 (2005) 164-165
5. Benlolo S., Lefoll C., Katchatouryan V., Payen D., and Mebazaa A. Successful use of levosimendan in a patient with peripartum cardiomyopathy. Anesth Analg 98 (2004) 822-824
6. Okumura H., Iuchi K., Yoshida T., et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 104 (2000) 158-163
7. Suzuki T., Hayashi D., Yamazaki T., et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 136 (1998) 362-363
8. Germanakis I., Kalmanti M., Parthenakis F., et al. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol 108 (2006) 212-215
9. Kyrzopoulos S., Adamopoulos S., Parissis J.T., et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol 99 (2005) 409-413
10. Mueller T., Gegenhuber A., and Haltmayer M. Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure. Int J Cardiol 104 (2005) 355-356